AstraZeneca plcC4X Discovery Holdings plc has exclusively licenced its NRF2 Activator programme to AstraZeneca and has got an upfront payment of $2m.
C4X Discovery Holdings plc has exclusively licenced its NRF2 Activator programme to AstraZeneca and has got an upfront payment of $2m.